Mineralys Therapeutics (MLYS) Accumulated Expenses (2022 - 2026)

Mineralys Therapeutics has reported Accumulated Expenses for 5 years, with the latest figure at $13.6 million in Q1 2026.

• Quarterly Accumulated Expenses rose 4.53% year-over-year to $13.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.6 million (up 4.53% YoY) and the FY2025 annual result came in at $13.1 million, down 7.56% from the prior year.
• Accumulated Expenses advanced to $13.6 million in Q1 2026 per MLYS's latest filing, from $13.1 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $28.2 million in Q3 2024 and troughed at $4.0 million in Q2 2023.
• A 5-year average of $14.4 million and a median of $13.3 million in 2025 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2024 and 2025: Accumulated Expenses jumped 565.42% in 2024, then slipped 28.78% in 2025.
• Over 5 years, Accumulated Expenses stood at $6.2 million in 2022, then soared by 60.41% to $9.9 million in 2023, then surged by 43.38% to $14.2 million in 2024, then slipped by 7.56% to $13.1 million in 2025, then rose by 3.86% to $13.6 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $13.6 million, $13.1 million, and $22.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.